T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$2B |
| 2 |
Sea Limited
SE
|
+$1.34B |
| 3 |
Morgan Stanley
MS
|
+$1.23B |
| 4 |
Incyte
INCY
|
+$1.05B |
| 5 |
Ross Stores
ROST
|
+$968M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Boeing
BA
|
+$2.05B |
| 2 |
VMW
VMware, Inc
VMW
|
+$1.5B |
| 3 |
Visa
V
|
+$1.16B |
| 4 |
JPMorgan Chase
JPM
|
+$1.13B |
| 5 |
Meta Platforms (Facebook)
META
|
+$1.12B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 25.44% |
| 2 | Healthcare | 17.77% |
| 3 | Consumer Discretionary | 14.38% |
| 4 | Financials | 11.9% |
| 5 | Communication Services | 10.82% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1251
Aprea Therapeutics
APRE
$8.3M
| $12.2M | ﹤0.01% |
+15,740
| New | +$10.3M |
|
1252
iShares iBoxx $ High Yield Corporate Bond ETF
HYG
$17.9B
| $12.2M | ﹤0.01% |
+149,000
| New | +$12M |
|
1253
iShares Core MSCI EAFE ETF
IEFA
$196B
| $12.1M | ﹤0.01% |
212,489
-48,974
| -19% | -$2.65M |
|
1254
FS Bancorp
FSBW
$323M
| $12M | ﹤0.01% |
624,258
+13,220
| +2% | +$258K |
|
1255
Newell Brands
NWL
$2.62B
| $12M | ﹤0.01% |
755,236
-49,492
| -6% | -$679K |
|
1256
Petrobras
PBR
$116B
| $11.9M | ﹤0.01% |
1,444,999
+416,047
| +40% | +$3.02M |
|
|
DISCK
1257
DELISTED
Discovery, Inc. Series C Common Stock
DISCK
| $11.9M | ﹤0.01% |
618,406
-33,450
| -5% | -$655K |
|
1258
Ichor Holdings
ICHR
$2.65B
| $11.9M | ﹤0.01% |
447,005
-1,623
| -0.4% | -$37.1K |
|
|
CDK
1259
DELISTED
CDK Global, Inc.
CDK
| $11.8M | ﹤0.01% |
284,930
-57,951
| -17% | -$2.23M |
|
1260
Regenxbio
RGNX
$707M
| $11.7M | ﹤0.01% |
316,348
-36,796
| -10% | -$1.37M |
|
1261
Assured Guaranty
AGO
$3.36B
| $11.6M | ﹤0.01% |
474,448
-33,544
| -7% | -$914K |
|
1262
Howmet Aerospace
HWM
$115B
| $11.5M | ﹤0.01% |
727,320
-301,220
| -29% | -$3.96M |
|
1263
Pinduoduo
PDD
$120B
| $11.5M | ﹤0.01% |
133,700
+122,800
| +1,127% | +$7.39M |
|
|
ELAT
1264
DELISTED
Elanco Animal Health Incorporated 5.00% Tangible Equity Units
ELAT
| $11.5M | ﹤0.01% |
296,769
-581,066
| -66% | -$23.5M |
|
|
AIV
1265
Aimco
AIV
$383M
| $11.4M | ﹤0.01% |
2,279,944
-133,253
| -6% | -$660K |
|
1266
Pentair
PNR
$10.5B
| $11.4M | ﹤0.01% |
300,096
-21,423
| -7% | -$754K |
|
|
EIDX
1267
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
| $11.3M | ﹤0.01% |
+236,150
| New | +$11M |
|
1268
Williams-Sonoma
WSM
$28.5B
| $11.2M | ﹤0.01% |
272,440
-17,660
| -6% | -$601K |
|
|
VER
1269
DELISTED
VEREIT, Inc.
VER
| $11.1M | ﹤0.01% |
344,841
+22,711
| +7% | +$632K |
|
|
CMA
1270
DELISTED
Comerica
CMA
| $11.1M | ﹤0.01% |
290,291
-15,553
| -5% | -$542K |
|
1271
Innoviva
INVA
$1.53B
| $11.1M | ﹤0.01% |
790,453
-10,931
| -1% | -$149K |
|
|
XENT
1272
DELISTED
Intersect ENT, Inc
XENT
| $11M | ﹤0.01% |
813,691
-3,689
| -0.5% | -$42.9K |
|
1273
Theravance Biopharma
TBPH
$880M
| $11M | ﹤0.01% |
524,461
+9,992
| +2% | +$257K |
|
1274
BHP
BHP
$220B
| $11M | ﹤0.01% |
247,348
-3,855
| -2% | -$151K |
|
1275
State Street SPDR Bloomberg High Yield Bond ETF
JNK
$7.32B
| $10.9M | ﹤0.01% |
+108,000
| New | +$10.8M |
|
Similar funds
T. Rowe Price Associates's Q2 2020 Portfolio in Review
As of Q2 2020, T. Rowe Price Associates held 2,591 positions worth $795B, up 26% from $632B the previous quarter. Its ten largest holdings account for 25% of the portfolio.
T. Rowe Price Associates's Q2 2020 filing shows 79 new, 1,096 increased, 1,255 reduced and 100 closed positions. Its largest new stake was Vroom Inc: 200,362 shares worth $797M. The largest sale was Boeing, an estimated $2.05B.
By sector, the portfolio is most concentrated in Technology at 25% of assets, up from 23% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q2 2020 buy was Vroom Inc: 200,362 shares worth $797M.
- T. Rowe Price Associates added most to Microsoft in Q2 2020, an estimated $2B increase.
- T. Rowe Price Associates's biggest Q2 2020 reduction was Boeing, cutting an estimated $2.05B.
- T. Rowe Price Associates fully exited Raytheon Company in Q2 2020, selling an estimated $1.01B.
- T. Rowe Price Associates's ten largest holdings make up 25% of its $795B portfolio in Q2 2020.
- T. Rowe Price Associates opened 79 new positions and closed 100 in Q2 2020.
- T. Rowe Price Associates's portfolio value rose 26% quarter-over-quarter to $795B.
Based on T. Rowe Price Associates's 13F filing for Q2 2020, filed 14 Aug 2020.